Pharmacotherapy for Patients with Atrial Fibrillation Who Receive Stents: Mix and Match? - C. Michael Gibson, MD

↳ This is a section part of Moment: CRT 2015 Coronary - Antiplatelet Controversy For ACS: How will this iMPACT our Practice?

Add this Moment to your Passport

Learn from this moment and keep it forever.

Add To Passport

$19.99

This moment is included in Simple Premium - Get started for free.

FREE with Simple Premium

Start your 30-day free trial

Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Preview

Summary

Pharmacotherapy for Patients with Atrial Fibrillation Who Receive Stents: Mix and Match? presented by C. Michael Gibson, MD at CRT 2015

Add this Moment to your Passport

Learn from this moment and keep it forever.

Add To Passport

$19.99

This moment is included in Simple Premium - Get started for free.

FREE with Simple Premium

Start your 30-day free trial

Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

Interventional Cardiologists
Interventional Fellows

Session Name: Antiplatelet Controversy For ACS: How will this iMPACT our Practice?

Track: Coronary

Learning Objectives

Update in advances in ACS & AMI Management

Other Components in this Moment

Emerging Protocols for Antiplatelet Therapy in ACS and During PCI - Roxana Mehran, MD

Why I Prefer Ticagrelor - Gary L. Schaer, MD

Why I Prefer Prasugrel - D. Angiolillo, MD, PhD

What Should Be the Role of Cangrelor in PCI Post-FDA Advisory Panel? - Neal S. Kleiman, MD

Cost Analysis: Is it still Cost Effective to Use Prasugrel or Ticagrelor vs. Generic Clopidogrel? - David J. Cohen, MD

Switching Back to Clopidogrel: Whether and When? - Paul A. Gurbel, MD

Pharmacotherapy for Patients with Atrial Fibrillation Who Receive Stents: Mix and Match? - C. Michael Gibson, MD

High Dose Tirofiban: Should it be Our Preferred GPI? - George W. Vetrovec, MD

Will The Results Form the DAPT Study Will Impact on the Duration Of DAPT in ACS Patients? - Dean J. Kereiakes, MD

Is There a Role for Antiplatelet Therapy with Vorapaxar Following ACS? - Sunjay Kaul, MD

Loading Simple Education